Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing
Authors:
- Paola FossaPaola Fossa
- Matteo UggeriMUMatteo Uggeri
- Alessandro OrroAOAlessandro Orro
- Chiara UrbinatiCUChiara Urbinati
- Alessandro RondinaAlessandro Rondina
- Maria MilanesiMMMaria Milanesi
- Nicoletta PedemonteNPNicoletta Pedemonte
- Emanuela PesceEPEmanuela Pesce
- Rita PadoanRPRita Padoan
- Robert C. FordRFRobert C. Ford
- Xin MengXMXin Meng
- Marco RusnatiMRMarco Rusnati
Open Access
- 14 October 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (20) , 12274
Abstract
Cystic fibrosis is a hereditary disease mainly caused by the deletion of the Phe 508 (F508del) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic reticulum and rapidly degraded by the ubiquitin/proteasome system. Cystic fibrosis remains a potentially fatal disease, but it has become treatable as a chronic condition due to some CFTR-rescuing drugs that, when used in combination, increase in their therapeutic effect due to a synergic action. Also, dietary supplementation of natural compounds in combination with approved drugs could represent a promising strategy to further alleviate cystic fibrosis symptoms. On these bases, we screened by in silico drug repositioning 846 small synthetic or natural compounds from the AIFA database to evaluate their capacity to interact with the highly druggable lumacaftor binding site of F508del-CFTR. Among the identified hits, nicotinamide (NAM) was predicted to accommodate into the lumacaftor binding region of F508del-CFTR without competing against the drug but rather stabilizing its binding. The effective capacity of NAM to bind F508del-CFTR in a lumacaftor-uncompetitive manner was then validated experimentally by surface plasmon resonance analysis. Finally, the capacity of NAM to synergize with lumacaftor increasing its CFTR-rescuing activity was demonstrated in cell-based assays. This study suggests the possible identification of natural small molecules devoid of side effects and endowed with the capacity to synergize with drugs currently employed for the treatment of cystic fibrosis, which hopefully will increase the therapeutic efficacy with lower doses.Keywords
Funding Information
- Fondazione Italiana Fibrosi Cistica (FFC #10/2019, FFC#9/2019, FFC#10/2021)
- Cystic Fibrosis Foundation (PEDEMO20G0)
- EU project EOSC-Pillar (857650)
- pan-European research infrastructure for Biobanking and BioMolecular Resources Research Infrastructure (BBMRI) (PIR01_00017)
- Ministero della Salute
This publication has 103 references indexed in Scilit:
- Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndromeProceedings of the National Academy of Sciences, 2012
- Sodium Oxybate for Narcolepsy with Cataplexy: Systematic Review and Meta-AnalysisJournal of Clinical Sleep Medicine, 2012
- Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiaeJournal of Visualized Experiments, 2012
- Niacinamide mitigated the acute lung injury induced by phorbol myristate acetate in isolated rat's lungsJournal of Biomedical Science, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profilingAmerican Journal of Physiology-Cell Physiology, 2011
- Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by the Flavonoid QuercetinAmerican Journal of Respiratory Cell and Molecular Biology, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Preliminary Evidence for Cell Membrane Amelioration in Children with Cystic Fibrosis by 5-MTHF and Vitamin B12 Supplementation: A Single Arm TrialPLOS ONE, 2009
- Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screeningJournal of Clinical Investigation, 2005